Administrative Core

行政核心

基本信息

  • 批准号:
    10526102
  • 负责人:
  • 金额:
    $ 24.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-22 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

Administration and Coordination Core Project Summary The administrative and coordination core of the proposed U54 Center for Spatiotemporal Tumor Analytics for Guiding Sequential Targeted Inhibitor : Immunotherapy Combinations (ST-Analytics is designed to promote and support the integrated research efforts of scientists from the ISB, Yale, and UCLA, as well as our Outreach program, our Pilot Projects and Cross-Consortium Projects. The scientific programs of ST-Analytics are designed to resolve how to best harness immunotherapy/targeted therapy sequential combinations for the treatment of solid tumors in the clinic, starting with a focus on metastatic cutaneous melanoma. This requires bringing together a cross-disciplinary mix of clinical, biological, physical, engineering, and computational scientists, as well as state-of-the-art, multiomic profiling tools, syngeneic mouse models, and a rich bio-repository of highly relevant patient tissues. Meeting the ST-Analytics scientific goals requires a responsive administrative structure that (i) promotes and enables effective communication and resource sharing between the ST-Analytics researchers and the broader Cancer Systems Biology Consortium (CSBC), (ii) establishes a highly interactive environment wherein ST-Analytics researchers can be good students and teachers of each other, (iii) promotes achieving the program specific aims in a timely manner, (iv) intervenes as early as possible when scientific and logistic conflicts arise, (v) promotes diversity in our scientific workforce through various mechanisms, including but not limited to seed project funding, outreach programs, and raising awareness of these critical issues during our remote and in-person meetings, and (vi) monitoring the scientific integrity and robustness of scientific designs. The ST-Analytics administrative CORE should facilitate the free flow of data, new ideas, experimental protocols, customized reagents, and biospecimens between the institutions. It should establish working relationships with other funded centers. It should facilitate clinical or commercial translation and educational outreach. It should encourage flexible thinking in anticipation of new opportunities or unexpected roadblocks. Finally, it should facilitate a healthy environment of self-evaluation.
行政和协调核心 项目摘要 拟议的U 54时空肿瘤分析中心的行政和协调核心, 指导性序贯靶向抑制剂:免疫治疗组合(ST-Analytics旨在 促进和支持来自ISB,耶鲁大学和UCLA的科学家的综合研究工作,以及我们的 外展计划,我们的试点项目和跨联盟项目。ST-Analytics的科学计划 旨在解决如何最好地利用免疫治疗/靶向治疗顺序组合, 实体瘤的临床治疗,从转移性皮肤黑色素瘤开始。这需要 汇集了临床,生物,物理,工程和计算的跨学科组合 科学家,以及最先进的多组学分析工具,同基因小鼠模型和丰富的生物储存库 高度相关的病人组织满足ST-Analytics的科学目标需要一个响应迅速的管理 结构,(i)促进和实现ST分析之间的有效沟通和资源共享 研究人员和更广泛的癌症系统生物学联盟(CSBC),(ii)建立一个高度互动的 环境,其中ST分析研究人员可以是好学生和老师的对方,(iii)促进 及时实现方案的具体目标,(四)在科学和 逻辑冲突出现,(v)通过各种机制促进我们科学工作队伍的多样性,包括 但不限于种子项目资金,推广计划,并提高对这些关键问题的认识, 我们的远程和面对面会议,以及(六)监测科学的科学完整性和稳健性, 的设计. ST分析管理核心应促进数据的自由流动,新的想法,实验 研究方案、定制试剂和机构间的生物标本。它应该建立工作 与其他资助中心的关系。它应便于临床或商业翻译和教育 外展它应该鼓励灵活的思维,以预期新的机会或意想不到的障碍。 最后,它应促进健康的自我评价环境。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James R. Heath其他文献

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
  • DOI:
    10.1186/s13073-023-01278-0
  • 发表时间:
    2024-01-06
  • 期刊:
  • 影响因子:
    11.200
  • 作者:
    Daniela Matuozzo;Estelle Talouarn;Astrid Marchal;Peng Zhang;Jeremy Manry;Yoann Seeleuthner;Yu Zhang;Alexandre Bolze;Matthieu Chaldebas;Baptiste Milisavljevic;Adrian Gervais;Paul Bastard;Takaki Asano;Lucy Bizien;Federica Barzaghi;Hassan Abolhassani;Ahmad Abou Tayoun;Alessandro Aiuti;Ilad Alavi Darazam;Luis M. Allende;Rebeca Alonso-Arias;Andrés Augusto Arias;Gokhan Aytekin;Peter Bergman;Simone Bondesan;Yenan T. Bryceson;Ingrid G. Bustos;Oscar Cabrera-Marante;Sheila Carcel;Paola Carrera;Giorgio Casari;Khalil Chaïbi;Roger Colobran;Antonio Condino-Neto;Laura E. Covill;Ottavia M. Delmonte;Loubna El Zein;Carlos Flores;Peter K. Gregersen;Marta Gut;Filomeen Haerynck;Rabih Halwani;Selda Hancerli;Lennart Hammarström;Nevin Hatipoğlu;Adem Karbuz;Sevgi Keles;Christèle Kyheng;Rafael Leon-Lopez;Jose Luis Franco;Davood Mansouri;Javier Martinez-Picado;Ozge Metin Akcan;Isabelle Migeotte;Pierre-Emmanuel Morange;Guillaume Morelle;Andrea Martin-Nalda;Giuseppe Novelli;Antonio Novelli;Tayfun Ozcelik;Figen Palabiyik;Qiang Pan-Hammarström;Rebeca Pérez de Diego;Laura Planas-Serra;Daniel E. Pleguezuelo;Carolina Prando;Aurora Pujol;Luis Felipe Reyes;Jacques G. Rivière;Carlos Rodriguez-Gallego;Julian Rojas;Patrizia Rovere-Querini;Agatha Schlüter;Mohammad Shahrooei;Ali Sobh;Pere Soler-Palacin;Yacine Tandjaoui-Lambiotte;Imran Tipu;Cristina Tresoldi;Jesus Troya;Diederik van de Beek;Mayana Zatz;Pawel Zawadzki;Saleh Zaid Al-Muhsen;Mohammed Faraj Alosaimi;Fahad M. Alsohime;Hagit Baris-Feldman;Manish J. Butte;Stefan N. Constantinescu;Megan A. Cooper;Clifton L. Dalgard;Jacques Fellay;James R. Heath;Yu-Lung Lau;Richard P. Lifton;Tom Maniatis;Trine H. Mogensen;Horst von Bernuth;Alban Lermine;Michel Vidaud;Anne Boland;Jean-François Deleuze;Robert Nussbaum;Amanda Kahn-Kirby;France Mentre;Sarah Tubiana;Guy Gorochov;Florence Tubach;Pierre Hausfater;Isabelle Meyts;Shen-Ying Zhang;Anne Puel;Luigi D. Notarangelo;Stephanie Boisson-Dupuis;Helen C. Su;Bertrand Boisson;Emmanuelle Jouanguy;Jean-Laurent Casanova;Qian Zhang;Laurent Abel;Aurélie Cobat
  • 通讯作者:
    Aurélie Cobat
C60's smallest cousin
C60 的最小“亲戚”
  • DOI:
    10.1038/31579
  • 发表时间:
    1998-06-25
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    James R. Heath
  • 通讯作者:
    James R. Heath
Protein Catalyzed Capture (PCC) Agents for Antigen Targeting.
用于抗原靶向的蛋白质催化捕获 (PCC) 试剂。
  • DOI:
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    M. Idso;B. Lai;Heather D Agnew;James R. Heath
  • 通讯作者:
    James R. Heath
Planar Patch-Clamp Electrodes for Single Cell and Neural Network Studies
  • DOI:
    10.1016/j.bpj.2009.12.3287
  • 发表时间:
    2010-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    John M. Nagarah;Daniel A. Wagenaar;James R. Heath
  • 通讯作者:
    James R. Heath
Stereochemical engineering of a peptide macrocycle allosteric inhibitor of phospho-Akt2 controls cell penetration by fine-tuning macrocycle-cell membrane interactions
磷酸 Akt2 肽大环变构抑制剂的立体化学工程通过微调大环 - 细胞膜相互作用来控制细胞渗透
  • DOI:
    10.26434/chemrxiv-2021-kldh7
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    5.9
  • 作者:
    Arundhati Nag;A. Mafi;Samir R Das;Mary Beth Yu;Belen Alvarez;W. Goddard;James R. Heath
  • 通讯作者:
    James R. Heath

James R. Heath的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James R. Heath', 18)}}的其他基金

Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)
用于指导序贯靶向抑制剂的时空肿瘤分析:免疫治疗组合(ST-Analytics)
  • 批准号:
    10708901
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
PROJECT 1: TIME-Based Spatiotemporal Cancer Immunograms Predictive for Immunotherapy-Targeted Therapy Sequential Combinations
项目 1:基于时间的时空癌症免疫图预测免疫治疗靶向治疗顺序组合
  • 批准号:
    10907268
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)
用于指导序贯靶向抑制剂的时空肿瘤分析:免疫治疗组合(ST-Analytics)
  • 批准号:
    10526101
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
PROJECT 1: TIME-Based Spatiotemporal Cancer Immunograms Predictive for Immunotherapy-Targeted Therapy Sequential Combinations
项目 1:基于时间的时空癌症免疫图预测免疫治疗靶向治疗顺序组合
  • 批准号:
    10526103
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10708920
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
PROJECT 1: TIME-Based Spatiotemporal Cancer Immunograms Predictive for Immunotherapy-Targeted Therapy Sequential Combinations
项目 1:基于时间的时空癌症免疫图预测免疫治疗靶向治疗顺序组合
  • 批准号:
    10708924
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
Data-driven Patient-Specific Agent Based Models of Metastatic Melanoma for Immunotherapy Response Prediction
用于免疫治疗反应预测的数据驱动的基于患者特异性药物的转移性黑色素瘤模型
  • 批准号:
    10831325
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
Nano and biomolecular engineered technologies for neoantigen-specific T cell capture and characterization
用于新抗原特异性 T 细胞捕获和表征的纳米和生物分子工程技术
  • 批准号:
    10297588
  • 财政年份:
    2021
  • 资助金额:
    $ 24.66万
  • 项目类别:
Nano and biomolecular engineered technologies for neoantigen-specific T cell capture and characterization
用于新抗原特异性 T 细胞捕获和表征的纳米和生物分子工程技术
  • 批准号:
    10489832
  • 财政年份:
    2021
  • 资助金额:
    $ 24.66万
  • 项目类别:
Nano and biomolecular engineered technologies for neoantigen-specific T cell capture and characterization
用于新抗原特异性 T 细胞捕获和表征的纳米和生物分子工程技术
  • 批准号:
    10673935
  • 财政年份:
    2021
  • 资助金额:
    $ 24.66万
  • 项目类别:

相似海外基金

Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
  • 批准号:
    10760051
  • 财政年份:
    2023
  • 资助金额:
    $ 24.66万
  • 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
  • 批准号:
    2303692
  • 财政年份:
    2023
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
  • 批准号:
    468168
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10427960
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
  • 批准号:
    10577074
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
  • 批准号:
    486588
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
  • 批准号:
    2760091
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10621188
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
  • 批准号:
    10891016
  • 财政年份:
    2021
  • 资助金额:
    $ 24.66万
  • 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
  • 批准号:
    10230365
  • 财政年份:
    2020
  • 资助金额:
    $ 24.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了